Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
looks like breakout is imminent
insert-text-here
AQS is very close to acquire rights up to 9 Marketed Products
with these Products aequus will have 11 Marketed Products so you can be sure that they will reach profitability very quickly . Now add Aequus other real Big drugs Oxcarbazepine XR ,Topiramate XR and AQS1301 which all three Drugs are expected to enter the Market by around mid 2018 with these Drugs revenue will explode to the upside i think peak sales for all the products mentioned above can hit $100 MILLION in revenue .Maybe now you guys understand why i say this goldmine with a dirt low market cap of US$15 million has 20 bagger potential and even that is conservative in the long term.
9 Products + Vististan + Tacrolimus = Peak Sales of $15 Million
Topiramate XR +Oxcarbazepine XR = Peak Sales of $40 Million
AQS1301 (AQS has global rights) = Peak Sales of minimum $50 million (USA alone)
Ceo Janzen is talking about these 4 drugs Topiramate XR Oxcarbazepine XR ,Vististan & Tacrolimus in the interview below
http://business.financialpost.com/midas-letter/podcast-aequus-pharmaceuticals-ceo-doug-janzen-on-the-low-cost-of-drug-commercialization-in-canada
Doug Janzen: We bought our commercial infrastructure last July, and since then we’ve launched two products and we’ve just licensed the two Supernus programs. Those four products, we think an aggregate can do $40 million, $45 million at peak sales.
AQS1301
NDA Filing for AQS-1301:Expected 3Q2017 Expected Commercial License (If Bioequivalence demonstrated in Phase I, Registration Study may NOT be required for Approval of AQS1301)
The Abilify brand and generic tablets had U.S. sales of approximately $3.1 billion MAT for the most recent twelve months ending in August 2016 according to IMS Health*.
this one will be over $10 before year end especially with positive phase 3 results .This is next ACAD in the making here
up she goes looks like another push towards 0.30 coming
Another product acquisition imminent , im very optimistic that this unknown stock will hit $1 before year end .
Must Watch to realize the mega potential here
First Phase 3 results expected within 3-4 months and the start of Phase 2/3 in Alzheimer’s disease(AD) agitation this quarter .More Infos on the conference below which begins in next hour .
Axsome Therapeutics, Inc. at 16th Annual Needham Healthcare Conference
Wednesday, April 5, 2017 8:40 a.m. ET
http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=254022&eventID=5251631
Looks like tree shaking to steal more cheap shares . AXSM is definitely one of the cheapest Nasdaq biotech i ever have seen before in last 18 years .GL
Market cap: $84 million
Cash: $50.6 Million
NEW Presentation April
http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NjY0Mzk1fENoaWxkSUQ9MzcyMTk4fFR5cGU9MQ==&t=1
Financial guidance: Recent financing extends estimated cash runway into the first quarter of 2019.
AXS-05 Treatment Resistant Depression in Phase 3 -(Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.)
AXS-05 Agitation in Alzheimer’s Disease in Phase 2/3 -(No approved medication = unmet medical need. 2M patients in the U.S.)
AXS-02 Complex Regional Pain Syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status) -(No approved drug = high unmet need. 80,000 new cases per year in the U.S.)
AXS-02 Knee Osteoarthritis (OA) with Bone Marrow Lesions (BMLs) in Phase 3 (SPA & Fast Track) -(7M patients in the U.S.)
AXS-02 Chronic Low Back Pain(CLBP) with Modic Changes (MCs) in Phase 3 -(1.6M patients in the U.S.)
Hey guys if you own shares of this low float stock then please put a high GTC sell order in to prevent your shares from being borrowed to short . This will help to drive this brutally undervalued stock much higher .Thank You
How to Prevent your Shares Holdings from being Shorted
www.contracts-for-difference.com/Borrowing-lending-shares.html
GREAT News out , this product alone could bring as much as $200 million in annual revenue and this unknown goldmine is value at laughable $14 million .This one has reallly 20 bagger potential if everything goes well .GL
Aequus Pharmaceuticals : Announces Positive Results from Second Proof of Concept Study for Long-Acting Aripiprazole Transdermal Patch
http://www.4-traders.com/AEQUUS-PHARMACEUTICALS-IN-27329675/news/Aequus-Pharmaceuticals-Announces-Positive-Results-from-Second-Proof-of-Concept-Study-for-Long-Acti-24148606/
The Abilifybrand and generic tablets had U.S. sales of approximately $3.1 billion MAT for the most recent twelve months ending in August 2016 according to IMS Health*.
MUST WATCH to realize the MEGA MONSTER POTENTIAL HERE
Axsome Therapeutics, Inc. at 16th Annual Needham Healthcare Conference (Live)
April 5, 2017 at 8:40 a.m. ET
MarketCap $95M /Cash $50M /5x Phase 3 = Definitely one of the most undervalued Biotech you can get in USA
Market Cap: $95 Million
Cash: $50 Million
Price: 4.17
http://biopharmcatalyst.com/companies/company-pipeline-database#sort=company
AXS-02 COAST-1 Knee Osteoarthritis Associated with Bone Marrow Lesions Phase 3 Phase 3 commenced March 2016. Interim analysis due 3Q 2017.
AXS-02 CREATE-1 Complex regional pain syndrome (CRPS) Phase 3 Initiated July 2015. Expect to complete trial by end of 2017 with interim efficacy analysis due 4Q 2017.
AXS-02 Chronic Low Back Pain Associated with Modic Changes Phase 3 Phase 3 initiation contingent upon resources.
AXS-05 Agitation in patients with Alzheimer’s disease (AD) Phase 2/3 Phase 2/3 to be initiated 2Q 2017.
AXS-05 STRIDE-1 Treatment resistant depression Phase 3 Phase 3 initiated March 2016. Top-line data due 1Q 2018.
looks like small consolidation before next leg up ..
Share offering is finished ..$5 or higher is still possible before Weekend
Axsome Therapeutics Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares ..
https://globenewswire.com/news-release/2017/03/29/946291/0/en/Axsome-Therapeutics-Announces-Full-Exercise-of-Underwriter-s-Option-to-Purchase-Additional-Shares.html
$5+ before weekend likely especially with good news
Hey guys if you own shares of this low float stock then please put a high GTC sell order in to prevent your shares from being borrowed to short . This will help to drive this brutally undervalued stock much higher .Thank You
How to Prevent your Shares Holdings from being Shorted
www.contracts-for-difference.com/Borrowing-lending-shares.html
look at main ticker AQS.V there is more action
AXSM running higher again guys still a terrible undervalued gem
here are the latest stock market analyst ratings:
Brean Capital began new coverage on Axsome Therapeutics, Inc. giving the company a “” rating. They now have a USD 20 price target on the stock.
Axsome Therapeutics, Inc. had its “” rating reiterated by analysts at Ladenburg Thalmann. They now have a USD 27 price target on the stock.
Cantor Fitzgerald began new coverage on Axsome Therapeutics, Inc. giving the company a “” rating. They now have a USD 13 price target on the stock.
AXSM is maybe the cheapest Nasdaq Biotech you can get with 5x Phase 3 in various indications and a laughable Market cap of $85 Million and $50 Million in cash .The fair value should be at $8-10 right now for this unknown Biotech .
Latest stock market analyst ratings:
Brean Capital began new coverage on Axsome Therapeutics, Inc. giving the company a “” rating. They now have a USD 20 price target on the stock.
Axsome Therapeutics, Inc. had its “” rating reiterated by analysts at Ladenburg Thalmann. They now have a USD 27 price target on the stock.
Cantor Fitzgerald began new coverage on Axsome Therapeutics, Inc. giving the company a “” rating. They now have a USD 13 price target on the stock.
The Cheapest Biotech you can get in USA with 5 Phase 3 in various indications and a laughable Market cap of $85 Million and $50 Million in cash .
AXSM (MC $83 M)(Cash $50 M) 4x BIG Phase 3 Ongoing with first interim results in 2H 2017
Very attractive and massive undervalued Biotech Stock with many Major News on the way . Axsome has 4 Phase 3 clinical trials ongoing in various indication targeting very large Markets .This Stock is brutally undervalued with Market cap of $83 million and $50 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) over 50% of O/S is owned by Insider and Institutions which is a good sign .
This undiscovered goldmine could be the next 10 bagger gem if just oneof their 4 Phase 3 program is successful .GL
Axsome (AXSM)
Market-Cap: $83 Million
Cash: $50.6 Million
Price:$3.60
Shares Out: 23 Million
Anticipated Near-Term Clinical Milestones
Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)
Clinical Trial Readouts:
-- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)
-- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)
-- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)
New Presentation
media.corporate-ir.net/media_files/IROL/25/254022/Axsome_Presentation_14_Mar_2017.pdf
Major Shareholders
Herriott Tabuteau, MD 7 351 729 38,4%
Fidelity Management & Research Co. 2 361 625 12,3%
JPMorgan Asset Management (UK) Ltd. 1 432 456 7,48%
Mark Coleman, MD 647 998 3,38%
BlackRock Fund Advisors 426 837 2,23%
Stifel Trust Co., NA 415 279 2,17%
The Vanguard Group, Inc. 272 189 1,42%
Lombard Odier Asset Management (USA) Corp. 250 000 1,31%
JPMorgan Investment Management, Inc. 156 625 0,82%
SSgA Funds Management, Inc. 134 688 0,70%
AXSM (MC $83 M)(Cash $50 M) 4x BIG Phase 3 Ongoing with first interim results in 2H 2017
Very attractive and massive undervalued Biotech Stock with many Major News on the way . Axsome has 4 Phase 3 clinical trials ongoing in various indication targeting very large Markets .This Stock is brutally undervalued with Market cap of $83 million and $50 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) over 50% of O/S is owned by Insider and Institutions which is a good sign .
This undiscovered goldmine could be the next 10 bagger gem if just oneof their 4 Phase 3 program is successful .GL
Axsome (AXSM)
Market-Cap: $83 Million
Cash: $50.6 Million
Price:$3.60
Shares Out: 23 Million
Anticipated Near-Term Clinical Milestones
Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)
Clinical Trial Readouts:
-- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)
-- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)
-- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)
New Presentation
media.corporate-ir.net/media_files/IROL/25/254022/Axsome_Presentation_14_Mar_2017.pdf
Major Shareholders
Herriott Tabuteau, MD 7 351 729 38,4%
Fidelity Management & Research Co. 2 361 625 12,3%
JPMorgan Asset Management (UK) Ltd. 1 432 456 7,48%
Mark Coleman, MD 647 998 3,38%
BlackRock Fund Advisors 426 837 2,23%
Stifel Trust Co., NA 415 279 2,17%
The Vanguard Group, Inc. 272 189 1,42%
Lombard Odier Asset Management (USA) Corp. 250 000 1,31%
JPMorgan Investment Management, Inc. 156 625 0,82%
SSgA Funds Management, Inc. 134 688 0,70%
AQS1301 Topline Results within 10 days = Push to $0.40+
and there are many big news on the way to push this dirt cheap and unknown goldmine higher .This will be the next 10+ bagger after Theratechnologies (TH.T) and BioSyent (RX.V) . AQS is maybe the cheapest Bio gem you can get in the US.
Market-Cap: $15 Million
Cash: $4 Million << enough untill mid 2018
Price: $0.20
AQS1301 topline results in 1Q 2017
Operational profitability estimated in 2017
File for CDN approval of Topiramate XR in 1H 2017
File for CDN approval of Oxcarbazepine XR in 1H 2017
Additional Product acquisitions in 2017
Partnership for AQS1301 in 2017
Two products launches to date (Tacrolimus IR and Vistitan™)
3 long-acting, transdermal programs in development, on track to file NDA in 2018
main listing is AQS.V on TSX-V Canada
Mcap $15M/ Cash till mid 2018/ HUGE Pipeline = MONSTER PICK HERE
This Stock is so terrible undervalued.....
Market-Cap: c$20.5 Million (US$15.15 Million)
Cash: c$5.1 Million << enough untill mid 2018
Price: $0.22
AQS1301 topline results in 1Q 2017
File for CDN approval of Topiramate XR in 1H 2017
File for CDN approval of Oxcarbazepine XR in 1H 2017
Additional Product acquisitions in 2017
Partnership for AQS1301 in 2017
Operational profitability estimated in 2017
Two products launches to date (Tacrolimus IR and Vistitan™)
3 long-acting, transdermal programs in development, on track to file NDA in 2018
AQS1301 topline results imminent(this month)
There is a lot of big news on the way which will drive the sp much higher again .the bought deal creates a fantastic buying opportunity
Aequus Successfully Completes Dosing in Second Proof of Concept Clinical Trial of Transdermal Aripiprazole Patch...
http://www.aequuspharma.ca/investors/press-release/aequus-successfully-completes-dosing-in-second-proof-of-concept-clinical-trial-of-transdermal-aripip
The Company expects to report topline results from this multi-dose study in the first quarter of 2017.
MC $20M /MEGA Pipeline /Close to Profitability /Cash until mid 2018 =TOP PICK 2017
AQSZF is close to profitability and to file 3 NDA and the whole company is valued at ridiculous $20 Million .This Stock should be at minimum $2+ right now .
http://www.aequuspharma.ca/Investors/AQS%20investor%20November%202016_web.pdf
File for CDN approval of Topiramate XR and Oxcarbazepine XR in 1H 2017
Operational profitability estimated in 2017
Additional Product Deals in 2017
Partnership for AQS1301 in 2017
Two products launches to date (Tacrolimus IR and Vistitan™)
3 long-acting, transdermal programs in development, on track to file NDA in 2018
MUST Watch
Great News out today ..Cannabinoid Patch =HUGE Potential
http://www.marketwired.com/press-release/aequus-licenses-rights-cannabinoid-transdermal-patch-treat-neurological-disorders-tsx-venture-aqs-2199996.htm
VANCOUVER, BC--(Marketwired - March 02, 2017) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company") announced today that through a previously announced Research Service Contract with Transdermal Research Pharma Lab ("TRPL") it has entered into a binding term sheet (the "Term Sheet") to acquire an exclusive world-wide license to a transdermal patch containing cannabinoids, for the use in epilepsy, Multiple Sclerosis (MS), and certain other neurological disorders.
Great Video out today
Ceo said there will be new Deals this Quarter so maybe thats why the interest in this stock .
djanzen@aequuspharma.ca Jan 6 at 10:13 PM
Hello XXX and Happy New Year… Thanks for your email.
The share price has been a negative surprise over the last few months. The business is going well, sales are growing and we expect additional commercial deals for revenue generating products to be announced this quarter. We also are about to start the second clinical trial for our transdermal Abilify product this month and our partner Corium has begun work on the next two transdermal programs. We have a lot of confidence in the business model and expect big things in 2017. Tax loss selling hurt the share price in December but in general the share price has been weaker than I expected. I personally bought 1million shares in 2016 and plan to buy more once I come out of a trading blackout. Our goal is to be profitable before the end of 2017 which at that point will remove the requirement for going to investors for financings.
Happy to chat if you would like to have a phone call…
Best, Doug Janzen Chairman and CEO / CoFounder Aequus Pharmaceuticals
Possible buyout in the making here
FDA acceptance for Amphetamine XR-Oral Suspension expected this or early next Week .
•Amphetamine XR-Oral Suspension —NDA Submitted Nov 15, 2016
•Cotempla (methylphenidate) XR-ODT —NDA resubmitted Dec 20, 2016
Burn-rate will drop now after their Drugs completed clincal trials and are under review by FDA . Im in for the run up with first Approval expected in 2Q and another one in 4Q . Cash is enough to keep them through 3Q so there is time to push the stock much higher especially with FDA approval .The Drugs are very attractive so maybe cash coming in through Partnerdeals even Buyout is possible because Neos is dirt cheap .
NEOS (MC $91 M) $60 M Cash 1 Drug approved /2 Drugs close to FDA approval targeting Billion Dollar Markets .
Very attractive and unknown FDA play with HUGE upside Potential i see thefair value around $20 per share .GL
NEOS Therapeutics (NEOS)
Market Cap: $91 M
Cash: $60 M
Price $5.90
Shares Out: 16.06 M
Presentation
http://investors.neostx.com/phoenix.zhtml?c=254075&p=irol-presentations
•Adzenys XR-ODT launched May, 2016
•Robust prescription growth since launch
•22,797 total TRx through December 2, 2016
•Pipeline includes two late-stage product candidates for the treatment of ADHD
•Amphetamine XR-Oral Suspension —NDA Submitted Nov 15, 2016
•Cotempla (methylphenidate) XR-ODT —NDA resubmitted Dec 20, 2016
NEOS (MC $95 M) $60 M Cash 1 Drug approved 2 more under review by FDA targeting Billion Dollar Markets .
Very attractive and unknown FDA play with HUGE upside Potential i see thefair value around $20 per share .GL
NEOS Therapeutics (NEOS)
Market Cap: $95 M
Cash: $60 M
Price $6
Shares Out: 16.06 M
Presentation
http://investors.neostx.com/phoenix.zhtml?c=254075&p=irol-presentations
•Adzenys XR-ODT launched May, 2016
•Robust prescription growth since launch
•22,797 total TRx through December 2, 2016
•Pipeline includes two late-stage product candidates for the treatment of ADHD
•Amphetamine XR-Oral Suspension —NDA Submitted Nov 15, 2016
•Cotempla (methylphenidate) XR-ODT —NDA resubmitted Dec 20, 2016
NEOS (MC $95 M) $60 M Cash 1 Drug approved 2 more under review by FDA targeting Billion Dollar Markets .
Very attractive and unknown FDA play with HUGE upside Potential i see thefair value around $20 per share .GL
NEOS Therapeutics (NEOS)
Market Cap: $95 M
Cash: $60 M
Price $6
Shares Out: 16.06 M
Presentation
http://investors.neostx.com/phoenix.zhtml?c=254075&p=irol-presentations
•Adzenys XR-ODT launched May, 2016
•Robust prescription growth since launch
•22,797 total TRx through December 2, 2016
•Pipeline includes two late-stage product candidates for the treatment of ADHD
•Amphetamine XR-Oral Suspension —NDA Submitted Nov 15, 2016
•Cotempla (methylphenidate) XR-ODT —NDA resubmitted Dec 20, 2016
(AQSZF)Got a great Reply by Ceo Janzen ..this unknown Goldmine should be at $2+ right now ...Bought my shares back in last few days .
djanzen@aequuspharma.ca Jan 6 at 10:13 PM
Hello XXX and Happy New Year… Thanks for your email.
The share price has been a negative surprise over the last few months. The business is going well, sales are growing and we expect additional commercial deals for revenue generating products to be announced this quarter. We also are about to start the second clinical trial for our transdermal Abilify product this month and our partner Corium has begun work on the next two transdermal programs. We have a lot of confidence in the business model and expect big things in 2017. Tax loss selling hurt the share price in December but in general the share price has been weaker than I expected. I personally bought 1million shares in 2016 and plan to buy more once I come out of a trading blackout. Our goal is to be profitable before the end of 2017 which at that point will remove the requirement for going to investors for financings.
Happy to chat if you would like to have a phone call…
Best, Doug Janzen Chairman and CEO / CoFounder Aequus Pharmaceuticals
Got a great Reply by Ceo Janzen ..this unknown Goldmine should be at $2+ right now ...Bought my shares back in last few days .
djanzen@aequuspharma.ca Jan 6 at 10:13 PM
Hello XXX and Happy New Year… Thanks for your email.
The share price has been a negative surprise over the last few months. The business is going well, sales are growing and we expect additional commercial deals for revenue generating products to be announced this quarter. We also are about to start the second clinical trial for our transdermal Abilify product this month and our partner Corium has begun work on the next two transdermal programs. We have a lot of confidence in the business model and expect big things in 2017. Tax loss selling hurt the share price in December but in general the share price has been weaker than I expected. I personally bought 1million shares in 2016 and plan to buy more once I come out of a trading blackout. Our goal is to be profitable before the end of 2017 which at that point will remove the requirement for going to investors for financings.
Happy to chat if you would like to have a phone call…
Best, Doug Janzen Chairman and CEO / CoFounder Aequus Pharmaceuticals